WEE1 and acute myeloid leukemia: However, the continued development of additional WEE1 targeting therapeutics, including WEE1 inhibitor ZN-c3 [44] and the WEE1 degrader ZNL 02-0096 [45], along with trials of adavosertib with cytarabine in AML (NCT02666950) may help pave the way for WEE1-targeting clinical studies for ALL.